Fred Poordad
0000-0002-1503-1569
Publication & Citation Trends
Most Cited Works
Publications
259 total
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening PDF
Cited by 1,002
OpenAlex
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence PDF
Cited by 457
OpenAlex
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis PDF
Cited by 874
OpenAlex
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
Cited by 373
OpenAlex
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Cited by 547
OpenAlex
Treating hepatitis C: current standard of care and emerging direct‐acting antiviral agents
Cited by 184
Semantic Scholar
Research Topics
Hepatitis C virus research
(169)
Liver Disease Diagnosis and Treatment
(145)
Hepatitis B Virus Studies
(85)
Liver Disease and Transplantation
(43)
HIV/AIDS drug development and treatment
(38)
Frequent Co-Authors
Affiliations
University of North Carolina at Chapel Hill
Cedars-Sinai Medical Center
West Los Angeles College
University of Arizona
Johns Hopkins University